Cytomegalovirus Cmv Infection Market

Cytomegalovirus (CMV) Infections

Overview

DelveInsight’s ‘Cytomegalovirus (CMV) Infections -Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the CMV Infections, historical and forecasted epidemiology as well as the CMV Infections market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The CMV Infections market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CMV Infections market size from 2018 to 2030. The Report also covers current CMV Infections treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2018–2030


Cytomegalovirus (CMV) Infections Disease Understanding and Treatment Algorithm

Cytomegalovirus (CMV) Infections Overview

As per the National Organization of Rare Disorders, Cytomegalovirus infection (CMV) is a viral infection that rarely causes obvious illness. The virus that causes CMV is part of the herpes virus family and, like other herpes viruses, may become dormant for a period of time and then be reactivated. CMV affects young children mainly, but it is estimated that by age 30 in the United States, half of all adults are, or have been, infected. The virus can pass from an infected, pregnant mother to her child through the shared blood supply (umbilical cord).

CMV is a member of the herpes virus family which includes the herpes simplex viruses and the viruses that cause chickenpox and mononucleosis. Human cytomegalovirus (HCMV) is a species of the Cytomegalovirus genus of viruses, of the viral family Herpes viridae or herpes viruses, and is the most common of all cytomegaloviruses.

The primary infection manifests as an asymptomatic or self-limited febrile illness in immuno-competent individuals, after which CMV establishes life-long latency in various cells which serve as reservoirs for reactivation and as carriers of infection to susceptible individuals.

Continued in the report…..

 

Cytomegalovirus (CMV) Infections Diagnosis

Most of the CMV infections go undiagnosed because the virus causes little to no symptoms. When a person is infected with CMV, antibodies (proteins) to the virus called IgM and/or IgG anti-CMV antibodies develop and stay in the body for the rest of the person's life. Once a CMV infection is suspected, a doctor conducts tests to detect the virus in body fluids or tissues. In newborns, the diagnosis is usually made by culturing the urine.

A blood test to detect the antibodies will be positive if the person has had a CMV infection. If the antibody test is negative, the person is considered to be uninfected with CMV. Serology tests are useful for determining whether a patient has had CMV infection in the past or not, by the presence or absence of CMV IgG.


Continued in the report…..

Cytomegalovirus (CMV) Infections Treatment

There are various approaches for the prevention of CMV. Major strategies for prevention are:

1.     Antiviral prophylaxis

2.     Pre-emptive therapy

Antiviral drugs for CMV prophylaxis are valganciclovir and oral or intravenous ganciclovir. For kidney recipients, valacyclovir is an alternative. In selected patient populations (heart and lung recipients), immunoglobulin preparations are occasionally used as an adjunct in combination with antiviral drugs. Acyclovir should NOT be used for anti-CMV prophylaxis. Infection with ganciclovir-resistant CMV has been associated with increased morbidity and mortality in SOT patients. The incidence is highest among lung transplant recipients.

Genotypic testing should be performed when resistance is suspected. In patients with low-level resistance to ganciclovir conferred by UL97 mutation, an increased dose of IV ganciclovir may be used (up to 10 mg/kg twice daily). Foscarnet is the preferred drug in high-level ganciclovir resistance, though cidofovir has been used occasionally. Reducing immunosuppression or switching from calcineurin to mTOR inhibitors such as sirolimus may be helpful. Experimental antiviral drugs that are being developed or considered for use in CMV resistant to ganciclovir, foscarnet, and cidofovir are letermovir and CMX-001 (orally available lipid prodrug of cidofovir).

Continued in the report…..


Cytomegalovirus (CMV) Infections Epidemiology           

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by  Total Diagnosed Cases of Cytomegalovirus (CMV) Infection, Number of Infants born with Congenital CMV, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT), Number of CMV Patients among SOT, Number of Refractory CMV Patients after HSCT/SOT, CMV Retinitis among HIV Patients scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.


Key Findings

  • In 2020, the total diagnosed cases of CMV were found out to be 111,959 in the 7MM, these cases are expected to grow at a CAGR of 0.13%, for the study period 2018–2020.
  • The estimates suggest higher diagnosed cases of CMV in the United States with 72,380 cases in 2020.
  • As per estimates, the US had the highest diagnosed cases of CMV, and among the EU5, France had the highest diagnosed population, followed by Germany.
  • Japan had 6,879 diagnosed cases of CMV in 2020.


Cytomegalovirus (CMV) Infections Epidemiology

The epidemiology segment also provides the CMV Infections epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Cytomegalovirus (CMV) Infections Drug Chapters

Cytomegalovirus (CMV) Infections Emerging Drugs

Triplex: Helocyte

Triplex is a first-in-class, best-in-class, universal (non-HLA-restricted) recombinant modified vaccinia ankara viral vector vaccine engineered to induce a robust and durable virus-specific T cell response to three immuno-dominant proteins linked to CMV complications in the transplant setting: UL83 (pp65), UL123 (IE1) and UL122 (IE2). The drug was developed in partnership with the National Cancer Institute by its lead investigator, Diamond, of the City of Hope.  In a phase I study, Triplex was found to be safe, well-tolerated, and highly immunogenic when administered to healthy volunteers.

Currently, phase II clinical trials are being conducted by Helocyte for the study of CMV control in allogeneic HSCT recipients, kidney transplants, and liver transplants.


Triplex is currently the subject of multiple ongoing and planned studies, one involving vaccination of the donor (followed by the recipient) in higher-risk stem cell transplant patients, potentially introducing CMV immunity sooner and positioning Triplex ahead of prophylactic antivirals in the standard of care.


V160: Merck

V160 is human cytomegalovirus (HCMV) with a genome of ~231-kb that includes the ~15- kb deletion present in the parental virus, AD169. Virions consist of a double-stranded linear DNA genome packaged into an icosahedral nucleocapsid that is surrounded by a proteinaceous tegument. This tegument is enveloped by a lipid bilayer containing a variety of viral glycoproteins. Virions have a diameter of ~200 nm. It is being developed by Merck in phase II clinical trial for the treatment of Cytomegalovirus (CMV) Infection, particularly in healthy women. The drug has already completed its phase I trial in healthy adults for the treatment of CMV infection.

Products detail in the report…


List to be continued in the report…


Cytomegalovirus (CMV) Infections Market Outlook

Cytomegalovirus (CMV), is extremely common worldwide. The global burden of Cytomegalovirus Infection has increased over the year (approximately 50% of US adults are infected with CMV). Among the seven major markets, the United States has reported having a maximum number of CMV patients. In most individuals, primary infection with CMV is asymptomatic, with the infected host showing no signs or symptoms of the disease.

Healthy people who are infected with CMV usually do not require medical treatment. Medications are available to treat CMV infection in people who have weakened immune systems and babies with signs of congenital CMV. For babies with signs of congenital CMV infection at birth, antiviral medications may improve hearing and developmental outcomes.


CMV infection or reactivation can lead to serious complications in hosts whose immune systems are either compromised by disease or suppressed, which is a common following stem cell and solid organ transplants.


Prophylactic Management

Transmission of cytomegalovirus is often preventable because it is most often transmitted through infected bodily fluids that come in contact with hands and then are absorbed through the nose or mouth of a susceptible person. There are two major strategies for CMV disease prevention after liver transplantation that includes preemptive therapy and antiviral prophylaxis.


For preemptive therapy, patients are monitored for evidence of CMV replication by sensitive assays, most commonly using quantitative nucleic acid amplification tests by PCR and less commonly by detection of pp65 antigenemia, and upon the detection of asymptomatic CMV replication, antiviral therapy is administered preemptively to prevent progression to symptomatic clinical disease.

CMV end-organ disease is best prevented using ART to maintain the CD4 count >100 cells/mm3. Before ART was widely available, the daily use of oral ganciclovir (no longer marketed in the United States) for primary prophylaxis significantly reduced the incidence of CMV disease in a randomized, placebo-controlled trial.


Although vaccines for CMV are still in the research and developmental stages, there are some treatment options. One study revealed that hyperimmune globulin, when given to pregnant women with CMV, may help prevent the fetus from contracting the infection. In 2005, a non-randomized study suggested that the administration of CMV-specific hyperimmune globulin (HIG) to pregnant women with primary CMV infection could lead to a significant decrease in the rate of MTCT (decreasing from 40% to 16%) and on the risk of congenital disease (decreasing from 50% to 3%). Subsequently, other non-randomized studies also showed improved outcomes in CMV-infected infants born to mothers who had received HIG in pregnancy, raising optimism around this strategy. However, in 2014 results of the first phase II randomized, placebo-controlled trial on the use of virus-specific HIG for the prevention of congenital CMV infection was published and revealed that the difference in the rate of congenital infection between the group of pregnant women who had received HIG and the placebo group was not statistically significant.


The study by Leruez et al., titled “In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study” evaluated the efficacy of high dose oral valacyclovir (8 g daily) in pregnant women carrying a moderately CMV infected fetus. The drug was well-tolerated in the study population. Using Simon’s optimal two-stage design, valacyclovir was assumed to have a positive effect if at least 31 per 43 neonates were asymptomatic at birth. Study results showed that the number of asymptomatic infants at birth was 34 per 43, implying the benefit of this therapeutic approach. Moreover, compared with a historical cohort, the use of valacyclovir significantly increased the proportion of asymptomatic neonates from 43% without treatment to 82% with treatment.


Therapeutic Management

Currently, antiviral drugs are used for CMV infection following transplant procedures. The drugs include valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination, etc. The several CMV infections caused due to CMV are retinitis, pneumonia, gastrointestinal ulcers, encephalitis, and others (mouth ulcers, pharyngitis, and others).

CMV infections can be controlled by drug therapy but, as yet, cannot be cured. Two drugs that keep the infection from getting worse are ganciclovir and foscarnet. These are delivered intravenously, and treatment must continue over a long period of time.

Continued in the report…..


Key Findings


  • The market size of Cytomegalovirus (CMV) Infections in the 7MM was estimated to be USD 1334.73 million in 2020, and it is estimated to grow at a Compound Annual Growth Rate (CAGR) of 12.38% for the study period (2018–2030).
  • According to the estimates, the highest market size of Cytomegalovirus (CMV) Infections was found in the United States, followed by France.
  • The market size of Prophylactic and therapeutic CMV Infection in seven major markets was USD 922.34 million and USD 412.38 million in 2020, respectively.
  • Among the EU5 countries, Germany had the highest Prophylactic market size with USD 56.07 million in 2020, while Italy had the lowest Prophylactic market size for CMV Infection with USD 34.56 million in 2020.


“The management of CMV infection is maintained by two approaches i.e. prophylaxis and therapeutic approach. Currently the market is dominated by the use of drugs like valganciclovir, valacyclovir hydrochloride, and others. However the market of these drugs will experience a drop in the market share due to the launch of new emerging therapies. Recently Prevymis got approval in 2017, entered the market in 2018. Prevymis covers a very small targeted population because it is approved only for the prophylaxis (prevention) of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). Hence, it is alright to say that it will show a positive impact on the market but it will not be responsible for the major increase in the market size. As the patent of prevymis is going to expire in 2029, there is an estimated decline in its market after 2029. Among the prophylactic potential market, two therapies, i.e., V160 and mRNA-1647 are targeting the same patient population, i.e., CMV-seronegative and CMV-seropositive healthy adults (childbearing women). And in therapeutic potential market, it is believed that Maribavir has the potential to be the promising agent in the US to treat Cytomegalovirus Infection.”

 

The United States Market Outlook

This section provides the total CMV Infections market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total CMV Infections market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total CMV Infections market size and market size by therapies in Japan are provided.


Cytomegalovirus (CMV) Infections Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the CMV Infections market or expected to get launched in the market during the study period 2018–2030. The analysis covers the CMV Infection market uptake by drugs; patient uptake by therapies; and sales of each drug.  

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Cytomegalovirus (CMV) Infections Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for CMV Infections emerging therapies.

Reimbursement Scenario in Cytomegalovirus (CMV) Infections

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the CMV Infections market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 


Scope of the Report

  • The report covers the descriptive overview of CMV Infections, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the CMV Infections epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for CMV Infections is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the CMV Infections market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM CMV Infections market.


Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the CMV Infections market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence CMV Infections R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for CMV Infections. The launch of emerging therapies will significantly impact the CMV Infections market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


Cytomegalovirus (CMV) Infections Report Insights

  • Patient Population
  • Therapeutic Approaches
  • CMV Infections Pipeline Analysis
  • CMV Infections Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Cytomegalovirus (CMV) Infections Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • CMV Infections Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Cytomegalovirus (CMV) Infections Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the CMV market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the CMV Infections total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest CMV Infections market size during the forecast period (2021–2030)?
  • At what CAGR, the CMV Infections market is expected to grow at the 7MM level during the forecast period (2021–2030)?
  • What would be the CMV Infections market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the CMV Infections market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of CMV Infections?
  • What is the historical CMV Infections patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of CMV Infections at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CMV Infections?
  • Out of the above-mentioned countries, which country would have the highest incident population of CMV Infections during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of CMV Infections along with the approved therapy?
  • What are the current treatment guidelines for the treatment of CMV Infections in the US and Europe?
  • What are the CMV Infections marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of CMV Infections?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of CMV Infections?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CMV Infections therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for CMV Infections and their status?
  • What are the key designations that have been granted for the emerging therapies for CMV Infections?
  • What are the 7MM historical and forecasted market of CMV Infections?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving CMV Infections.
  • To understand the future market competition in the CMV Infections market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for CMV Infections in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the CMV Infections market.
  • To understand the future market competition in the CMV Infections market.

1. Key Insights

2. Executive Summary of Cytomegalovirus (CMV) Infection

3. Competitive Intelligence Analysis for Cytomegalovirus (CMV) Infection

4. Cytomegalovirus (CMV) Infection: Market Overview at a Glance

4.1. Cytomegalovirus (CMV) Infection Total Market Share (%) Distribution in 2017

4.2. Cytomegalovirus (CMV) Infection Total Market Share (%) Distribution in 2030

5. Cytomegalovirus (CMV) Infection: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Cytomegalovirus (CMV) Infection Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Cytomegalovirus (CMV) Infection Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Cytomegalovirus (CMV) Infection Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Cytomegalovirus (CMV) Infection Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Cytomegalovirus (CMV) Infection Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Cytomegalovirus (CMV) Infection Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Cytomegalovirus (CMV) Infection Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Cytomegalovirus (CMV) Infection Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Cytomegalovirus (CMV) Infection Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Cytomegalovirus (CMV) Infection Treatment and Management

8.2. Cytomegalovirus (CMV) Infection Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Cytomegalovirus (CMV) Infection Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Cytomegalovirus (CMV) Infection: Seven Major Market Analysis

13.1. Key Findings

13.2. Cytomegalovirus (CMV) Infection Market Size in 7MM

13.3. Cytomegalovirus (CMV) Infection Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Cytomegalovirus (CMV) Infection Total Market Size in the United States

15.1.2. Cytomegalovirus (CMV) Infection Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Cytomegalovirus (CMV) Infection Total Market Size in Germany

15.3.2. Cytomegalovirus (CMV) Infection Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Cytomegalovirus (CMV) Infection Total Market Size in France

15.4.2. Cytomegalovirus (CMV) Infection Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Cytomegalovirus (CMV) Infection Total Market Size in Italy

15.5.2. Cytomegalovirus (CMV) Infection Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Cytomegalovirus (CMV) Infection Total Market Size in Spain

15.6.2. Cytomegalovirus (CMV) Infection Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Cytomegalovirus (CMV) Infection Total Market Size in the United Kingdom

15.7.2. Cytomegalovirus (CMV) Infection Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Cytomegalovirus (CMV) Infection Total Market Size in Japan

15.8.3. Cytomegalovirus (CMV) Infection Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Cytomegalovirus (CMV) Infection

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 

Table 1 : 7MM Cytomegalovirus (CMV) Infection Epidemiology (2017-2030)

Table 2 : 7MM Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases (2017-2030)

Table 3 : Disease% Epidemiology in the United States (2017-2030)

Table 4 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 : Cytomegalovirus (CMV) Infection Epidemiology in Germany (2017-2030)

Table 6 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 : Cytomegalovirus (CMV) Infection Epidemiology in France (2017-2030)

Table 8 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in France (2017-2030) 

Table 9 : Cytomegalovirus (CMV) Infection Epidemiology in Italy (2017-2030)

Table 10 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 : Cytomegalovirus (CMV) Infection Epidemiology in Spain (2017-2030)

Table 12 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 : Cytomegalovirus (CMV) Infection Epidemiology in the UK (2017-2030)

Table 14 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in the UK (2017-2030)

Table 15 : Cytomegalovirus (CMV) Infection Epidemiology in Japan (2017-2030)

Table 16 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in Japan (2017-2030)

Table 17 : Drug Name, Clinical Trials by Recruitment status

Table 18 : Drug Name, Clinical Trials by Zone

Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Table 20 : Region-wise Market Size in USD, Million (2017-2030)

Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Table 22 : United States Market Size in USD, Million (2017-2030)

Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Table 24 : Germany Market Size in USD, Million (2017-2030)

Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Table 26 : France Market Size in USD, Million (2017-2030)

Table 27 : France Market Size by Therapy in USD, Million (2017-2030)

Table 28 : Italy Market Size in USD, Million (2017-2030)

Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Table 30 : Spain Market Size in USD, Million (2017-2030)

Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Table 32 : United Kingdom Market Size in USD, Million (2017-2030)

Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Table 34 : Japan Market Size in USD, Million (2017-2030)

Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of tables is not exhaustive; the final content may vary

Figure 1 : 7MM Cytomegalovirus (CMV) Infection Epidemiology (2017-2030)

Figure 2 : 7MM Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Cytomegalovirus (CMV) Infection Epidemiology in the United States (2017-2030)

Figure 4 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Cytomegalovirus (CMV) Infection Epidemiology in Germany (2017-2030)

Figure 6 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Cytomegalovirus (CMV) Infection Epidemiology in France (2017-2030)

Figure 8 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in France (2017-2030) 

Figure 9 : Cytomegalovirus (CMV) Infection Epidemiology in Italy (2017-2030)

Figure 10 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Cytomegalovirus (CMV) Infection Epidemiology in Spain (2017-2030)

Figure 12 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Cytomegalovirus (CMV) Infection Epidemiology in the UK (2017-2030)

Figure 14 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Cytomegalovirus (CMV) Infection Epidemiology in Japan (2017-2030)

Figure 16 : Cytomegalovirus (CMV) Infection Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of figures is not exhaustive; the final content may vary.

  • Tags:
  • Cytomegalovirus (CMV) Infection mar...
  • Cytomegalovirus (CMV) Infection mar...
  • Cytomegalovirus (CMV) Infection mar...
  • Cytomegalovirus (CMV) Infection mar...
  • Cytomegalovirus (CMV) Infection mar...
  • Cytomegalovirus (CMV) Infection mar...
  • Cytomegalovirus (CMV) Infection pip...
  • Cytomegalovirus (CMV) Infection tre...
  • Cytomegalovirus (CMV) Infection dru...
  • Cytomegalovirus (CMV) Infection sal...
  • Cytomegalovirus (CMV) Infection mar...
  • Cytomegalovirus (CMV) Infection dis...
  • Cytomegalovirus (CMV) Infection epi...
  • Cytomegalovirus (CMV) Infection

Forward to Friend

Need A Quote